The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Pletaal     6-[4-(1-cyclohexyltetrazol-5- yl)butoxy]-3...

Synonyms: Pletal, cilostazol, Cilostazole, Cilostazolum, CHEMBL799, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Pletaal


Psychiatry related information on Pletaal

  • METHODS AND RESULTS: In the present study 642 patients who underwent stenting were randomized to treatment either with cilostazol + aspirin (C group, 321 patients) or ticlopidine + aspirin (T group, 321 patients) [4].

High impact information on Pletaal


Chemical compound and disease context of Pletaal


Biological context of Pletaal


Anatomical context of Pletaal


Associations of Pletaal with other chemical compounds


Gene context of Pletaal


Analytical, diagnostic and therapeutic context of Pletaal


  1. The US experience with cilostazol in treating intermittent claudication. Hiatt, W.R. Atherosclerosis. Supplements. (2005) [Pubmed]
  2. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Matsumoto, M. Atherosclerosis. Supplements. (2005) [Pubmed]
  3. Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions. Iwama, D., Miyamoto, K., Miyahara, S., Tamura, H., Tsujikawa, A., Yamashiro, K., Kiryu, J., Yoshimura, N. J. Thromb. Haemost. (2007) [Pubmed]
  4. Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. Takeyasu, N., Watanabe, S., Noguchi, Y., Ishikawa, K., Fumikura, Y., Yamaguchi, I. Circ. J. (2005) [Pubmed]
  5. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Morishita, R. Atherosclerosis. Supplements. (2005) [Pubmed]
  6. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Goto, S. Atherosclerosis. Supplements. (2005) [Pubmed]
  7. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Comerota, A.J. Atherosclerosis. Supplements. (2005) [Pubmed]
  8. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Dawson, D.L., Cutler, B.S., Meissner, M.H., Strandness, D.E. Circulation (1998) [Pubmed]
  9. Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. Wu, S.N., Liu, S.I., Huang, M.H. Endocrinology (2004) [Pubmed]
  10. Drug treatment of intermittent claudication. Jacoby, D., Mohler, E.R. Drugs (2004) [Pubmed]
  11. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. Choi, J.M., Shin, H.K., Kim, K.Y., Lee, J.H., Hong, K.W. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  12. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats. Sasaki, H., Naka, K., Kishi, Y., Furuta, M., Sanke, T., Mukoyama, M., Nanjo, K. Exp. Neurol. (1997) [Pubmed]
  13. Comparison of the protective effects of type iii phosphodiesterase (pde3) inhibitor (cilostazol) and acetylsalicylic Acid on intestinal microcirculation after ischemia reperfusion injury in mice. Iba, T., Kidokoro, A., Fukunaga, M., Takuhiro, K., Ouchi, M., Ito, Y. Shock (2006) [Pubmed]
  14. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Beebe, H.G., Dawson, D.L., Cutler, B.S., Herd, J.A., Strandness, D.E., Bortey, E.B., Forbes, W.P. Arch. Intern. Med. (1999) [Pubmed]
  15. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Inoue, T., Uchida, T., Sakuma, M., Imoto, Y., Ozeki, Y., Ozaki, Y., Hikichi, Y., Node, K. J. Am. Coll. Cardiol. (2004) [Pubmed]
  16. Effect of cilostazol on experimental diabetic neuropathy in the rat. Kihara, M., Schmelzer, J.D., Low, P.A. Diabetologia (1995) [Pubmed]
  17. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hayashi, S., Morishita, R., Matsushita, H., Nakagami, H., Taniyama, Y., Nakamura, T., Aoki, M., Yamamoto, K., Higaki, J., Ogihara, T. Hypertension (2000) [Pubmed]
  18. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Aoki, M., Morishita, R., Hayashi, S., Jo, N., Matsumoto, K., Nakamura, T., Kaneda, Y., Ogihara, T. Diabetologia (2001) [Pubmed]
  19. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Tanaka, K., Gotoh, F., Fukuuchi, Y., Amano, T., Uematsu, D., Kawamura, J., Yamawaki, T., Itoh, N., Obara, K., Muramatsu, K. Stroke (1989) [Pubmed]
  20. The clinical features and treatment of arteriosclerosis obliterans with diabetes. Tsushima, N., Matsuo, H., Hayashi, T., Homma, S. Diabetes (1996) [Pubmed]
  21. Current medical therapies for patients with peripheral arterial disease: a critical review. Regensteiner, J.G., Hiatt, W.R. Am. J. Med. (2002) [Pubmed]
  22. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Morishita, R., Higaki, J., Hayashi, S.I., Yo, Y., Aoki, M., Nakamura, S., Moriguchi, A., Matsushita, H., Matsumoto, K., Nakamura, T., Ogihara, T. Diabetologia (1997) [Pubmed]
  23. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Zhang, W., Ke, H., Colman, R.W. Mol. Pharmacol. (2002) [Pubmed]
  24. Role of cyclic 3',5'-adenosine monophosphate in the regulation of chemical mediator release and cytokine production from cultured human mast cells. Shichijo, M., Inagaki, N., Kimata, M., Serizawa, I., Saito, H., Nagai, H. J. Allergy Clin. Immunol. (1999) [Pubmed]
  25. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Yang, R., Powell-Braxton, L., Ogaoawara, A.K., Dybdal, N., Bunting, S., Ohneda, O., Jin, H. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  26. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation. Park, S.Y., Lee, J.H., Kim, C.D., Lee, W.S., Park, W.S., Han, J., Kwak, Y.G., Kim, K.Y., Hong, K.W. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  27. Cilostazol: therapeutic potential against focal cerebral ischemic damage. Hong, K.W., Lee, J.H., Kima, K.Y., Park, S.Y., Lee, W.S. Curr. Pharm. Des. (2006) [Pubmed]
  28. Role of adjunct pharmacologic therapy in the era of drug-eluting stents. Douglas, J.S. Atherosclerosis. Supplements. (2005) [Pubmed]
  29. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Shinoda-Tagawa, T., Yamasaki, Y., Yoshida, S., Kajimoto, Y., Tsujino, T., Hakui, N., Matsumoto, M., Hori, M. Diabetologia (2002) [Pubmed]
  30. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. Birk, S., Kruuse, C., Petersen, K.A., Jonassen, O., Tfelt-Hansen, P., Olesen, J. J. Cereb. Blood Flow Metab. (2004) [Pubmed]
  31. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Woo, S.K., Kang, W.K., Kwon, K.I. Clin. Pharmacol. Ther. (2002) [Pubmed]
WikiGenes - Universities